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Introduction
Immune checkpoint inhibitors (ICIs) have revolutionized the prog-
nosis of several aggressive cancers, notably non–small cell lung 
cancer (NSCLC). Recent impressive results of large phase III trials 
in NSCLC have reported unprecedented improvements in overall 
survival and progression-free survival when anti–programmed 
death receptor 1 or anti–programmed death ligand 1 (anti–
PD-[L]1) was used in first-line therapy (1, 2). Likewise, remarkable 
5-year survival rates of 16% have recently been reported in this 
disease (3), highlighting the ability of these agents to provide long-
term tumor control. Although these results are encouraging, they 
also reinforce the fact that still only a minority of patients receive 
long-term benefit. Better understanding of the determinants of 
response to ICIs and identification of rational combinations that 
would increase the proportion of patients benefiting from these 
therapies are therefore crucial.
Several factors have been associated with response to immu-
notherapy: tumor-related factors (e.g., cancer cell mutations), 
microenvironment-related factors (e.g., expression of immune 
checkpoints, lymphocytic infiltration, or IFN signatures), and 
host-related factors (e.g., microbiome) (4). Defects in the DNA 
damage response (DDR) in cancer cells are key determinants of 
cancer immunogenicity. Indeed, DDR defects result in genomic 
instability and increased tumor mutational burden (TMB), which 
has been linked — at least in some cases — to better outcome 
upon ICI treatment (5). The best illustrations of this are proba-
bly mismatch repair-deficient tumors (6) and POLE/POLD1-mu-
tated endometrial carcinoma and glioblastoma (7, 8), which are 
highly sensitive to ICIs, likely due to their increased neoanti-
gen repertoire. High TMB has also been correlated with better 
response to ICIs in melanoma (9) and NSCLC (2, 10, 11). Oth-
er DNA repair defects, such as BRCA1/2 mutations, have been 
found to be enriched in ICI responders (12). However, a simple 
correlation among DNA repair defect–induced genomic instabil-
ity, TMB, and response to ICIs cannot be claimed (5), as tumor 
heterogeneity (13) and other determinants of response also play 
a role that, importantly, seems to be independent from TMB in 
response to ICIs (14, 15).
The cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway detects cytosolic DNA to activate innate 
immune responses. Poly(ADP-ribose) polymerase inhibitors (PARPi) selectively target cancer cells with DNA repair 
deficiencies such as those caused by BRCA1 mutations or ERCC1 defects. Using isogenic cell lines and patient-derived samples, 
we showed that ERCC1-defective non–small cell lung cancer (NSCLC) cells exhibit an enhanced type I IFN transcriptomic 
signature and that low ERCC1 expression correlates with increased lymphocytic infiltration. We demonstrated that clinical 
PARPi, including olaparib and rucaparib, have cell-autonomous immunomodulatory properties in ERCC1-defective NSCLC 
and BRCA1-defective triple-negative breast cancer (TNBC) cells. Mechanistically, PARPi generated cytoplasmic chromatin 
fragments with characteristics of micronuclei; these were found to activate cGAS/STING, downstream type I IFN signaling, 
and CCL5 secretion. Importantly, these effects were suppressed in PARP1-null TNBC cells, suggesting that this phenotype 
resulted from an on-target effect of PARPi on PARP1. PARPi also potentiated IFN-γ–induced PD-L1 expression in NSCLC cell 
lines and in fresh patient tumor cells; this effect was enhanced in ERCC1-deficient contexts. Our data provide a preclinical 
rationale for using PARPi as immunomodulatory agents in appropriately molecularly selected populations.
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(26, 27) and PARP inhibitors (PARPi) (28, 29), and while PARPi 
have demonstrated their efficacy in advanced BRCA-deficient 
breast cancers (30), these agents are also being clinically assessed 
in ERCC1-defective (platinum-sensitive) NSCLC (PIPSeN tri-
al, NCT02679963). Therefore, ERCC1 deficiency represents an 
attractive candidate for harnessing cGAS/STING activation in 
NSCLC, where ICIs have shown unprecedented efficacy, yet in 
only a small proportion of patients.
Here, we show that loss of ERCC1 in NSCLC leads to 
increased STING expression and constitutive activation of type 
I IFN signaling, which associates with enhanced T cell infiltra-
tion in patient-derived samples. Using a unique combination of 
isogenic models of ERCC1-deficient NSCLC, BRCA1-deficient 
and PARPi-resistant TNBC, we find that multiple clinical PARPi 
generate cytosolic DNA in a cell cycle– and DDR defect–depen-
dent fashion, as a result of an on-target effect of PARPi. This in 
turn activates cGAS/STING signaling and elicits specific tumor 
cell–intrinsic immune responses, including type I IFN response 
and CCL5 secretion. PARPi further synergize with IFN-γ to induce 
cell surface PD-L1 expression in NSCLC models, a phenotype that 
is specifically enhanced in ERCC1-deficient cells. Our data reveal 
an unexpected immunomodulatory potential of PARPi that could 
be therapeutically exploited to enhance ICI efficacy in ERCC1- 
deficient NSCLC patients.
Results
ERCC1 deficiency in isogenic systems is associated with increased 
type I IFN signaling, cytokine signaling, and lymphocytic infiltration 
in NSCLC. We hypothesized that lack of function of a key DNA 
repair tumor suppressor gene, such as ERCC1, in tumor cells, 
might influence the molecular processes that control antitumor 
cell immune responses. To address this hypothesis in a relatively 
unbiased fashion, we first used RNA-Seq to profile the transcrip-
tome of isogenic ERCC1-defective and WT A549 NSCLC cells (31, 
32). Briefly, this isogenic model was generated using zinc finger tar-
geting of ERCC1, and consists of one A549-ERCC1WT/WT parental 
cell line; one ERCC1-heterozygous cell line (herein referred to as 
A549-ERCC1+/–); and 3 ERCC1–/– clones, in which we reconfirmed 
no detectable levels of ERCC1 (Figure 1, A and B) and which are 
characterized by exquisite sensitivity to cisplatin (31) — highlight-
ing their clinical relevance (26) — and to PARPi (28) (Supplemental 
Figure 1A). Comparative transcriptomics of A549-ERCC1WT/WT and 
one ERCC1–/– clone (c216, referred to as A549-ERCC1–/– below) 
revealed 1486 significantly differentially expressed genes (DEGs; 
Figure 1C). Consistent with the known functions of the ERCC1/
XPF endonuclease in the resolution of stalled replication fork and 
subsequent appropriate cell cycle progression, gene set enrichment 
analysis (GSEA) using the REACTOME pathway database revealed 
significant downregulation of several DNA repair–, cell cycle–, and 
DNA replication–related pathways in A549-ERCC1–/– cells (Fig-
ure 1D and Supplemental Figure 1B). This analysis also identified 
significant enrichment of numerous immune-related pathways in 
A549-ERCC1–/– cells — indeed, 24 immune-related pathways were 
found among the top 50 upregulated REACTOME terms (Supple-
mental Figure 1C) — suggesting a role for ERCC1 in modulating the 
immune characteristics of NSCLC cells in a cell-autonomous fash-
ion. Among these pathways, the most significantly enriched were 
Another interface between DDR and immunogenicity that 
has recently generated particular attention in immuno-oncology 
is the cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/
STING) pathway (16). This pathway, involved in the sensing of for-
eign or damaged cytosolic DNA, triggers innate immune responses 
through the activation of a signaling cascade connecting the cyto-
plasmic DNA sensor cGAS, several signal transducers including 
STING and TBK1, and eventually transcription factors (mainly IRF3 
and NF-κB) that are collectively responsible for the induction of a 
type I IFN response (16). Thus, processes that disrupt nuclear DNA 
integrity and favor the translocation of DNA to the cytosol (either 
in the context of endogenous DNA repair deficiency or through 
the use of exogenous DNA-damaging agents) may activate cGAS/
STING. For example, defects in homologous recombination (HR) 
genes (BRCA1/2 or FANCD2) and use of radiotherapy or S phase–
dependent chemotherapies have been associated with cell cycle–
dependent formation of cytoplasmic chromatin fragments (CCFs) 
and subsequent increase in STING signaling in breast cancer (17–
20). Further, cGAS recently appeared to be an essential mediator 
of the antitumor effects of ICIs (21), and identification of cGAS/
STING activators has become an area of intense research, with sev-
eral ongoing phase I trials evaluating such molecules (22). As one of 
the main therapeutic challenges in immuno-oncology is currently to 
turn “cold,” non–T cell–inflamed tumors into “hot,” T cell–inflamed 
tumors, a better understanding of the cellular contexts in which tar-
geted therapies can activate the cGAS/STING pathway is key.
DDR-deficient cancers that present elevated genomic insta-
bility may represent a favorable environment for selective cGAS/
STING activation. Excision repair cross-complementation group 
1 (ERCC1) deficiency is the most frequent DDR defect in NSCLC 
and occurs in 30%–50% of cases (23). The tumor suppressor pro-
tein BRCA1 is also frequently defective in triple-negative breast 
cancer (TNBC), following either germline mutation or somatic 
alteration (mutation or epigenetic silencing) (24, 25). Both ERCC1 
and BRCA1 defects confer sensitivity to platinum-based therapy 
Figure 1. Loss of ERCC1 results in increased type I IFN and cytokine 
signaling in NSCLC models in vitro. (A) Schematic of the generation 
of ERCC1-deficient clones from the parental NSCLC cell line A549. Full 
procedures are detailed in Friboulet et al. (31). (B) Western blot showing 
expression of ERCC1 in the parental (ERCC1WT/WT), heterozygous (ERCC1+/–), 
and ERCC1-knockout clones (c216, c295, and c375). (C) Heatmap display-
ing all significantly differentially expressed genes (significantly DEGs) in 
A549-ERCC1–/– cells compared with A549-ERCC1WT/WT cells, determined 
by RNA-Seq. n = 3; heatmap scale is a Z score. Threshold for differen-
tial expression was |LFC| > 1, and threshold for significance was FDR < 
0.05. (D) GSEA of REACTOME pathways in A549-ERCC1–/– compared with 
A549-ERCC1WT/WT cells. Red, top 10 upregulated REACTOME pathways in 
A549-ERCC1–/– cells; yellow, top 10 downregulated REACTOME pathways in 
A549-ERCC1–/– cells. All pathways displayed had FDR < 0.05. AP folding*, 
antigen presentation folding assembly; Processing of capped intron*, 
processing of capped intron containing pre-mRNA; Interactions between 
a lymphoid cell and others*, interaction between a lymphoid cell and 
non-lymphoid cells. (E) GSEA of the REACTOME pathway “IFN-α/β signal-
ing,” and associated heatmap showing the genes of the pathway, ranked 
by FDR. n = 3; heatmap scale is a Z score. (F) GSEA of the REACTOME 
pathway “Cytokine signaling in immune system,” and associated heatmap 
showing the genes of the pathway, ranked by FDR. n = 3; heatmap scale is 
a Z score. In E and F, purple, significantly DEGs with FDR < 0.05 and |LFC| 
> 1; gray, nonsignificantly DEGs.
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NES = 2.79, FDR = 0.0063 for c375; Supplemental Figure 2, A–D). 
As ERCC1- deficient NSCLC tumors still harbor residual levels of 
ERCC1, we sought to investigate which threshold of ERCC1 defi-
ciency was sufficient to induce such a type I IFN signature in vitro 
by using the ERCC1-heterozygous cell line of our isogenic model 
(A549- ERCC1+/– cell line). Interestingly, the type I IFN signature 
was also significantly enriched in this model, albeit to a lesser 
extent than in ERCC1–/– clones (NES = 1.86; FDR = 0.0131; Supple-
mental Figure 2, E and F). Whole exome sequencing of the isogenic 
clones did not identify mutations in any gene involved in immune 
signaling (28), suggesting the defect in ERCC1 as the most likely 
cause of the observed transcriptional dysregulation.
In other contexts, DDR defects have been linked to innate 
immune response and type I IFN signaling via cytosolic DNA 
sensing, notably involving the cGAS/STING pathway (16, 17). We 
hypothesized that loss of ERCC1 might modulate such signals. 
Although expression of STING, the major initiator of the cytoso-
lic DNA–sensing pathway, was almost undetectable by Western 
blotting in A549-ERCC1WT/WT and A549-ERCC1+/– cells, we found 
elevated STING protein expression in A549-ERCC1–/– cells (Fig-
ure 2A). Consistent with this, STING mRNA levels were increased 
more than 2.5-fold in A549-ERCC1–/– cells (log2 fold change [LFC] 
= 1.3769, FDR = 0.0009), compatible with a transcriptional mode 
of regulation. A similar upregulation of STING was also detected 
type I and II IFN signaling, antigen presentation through class I 
major histocompatibility complex (MHC-I), and innate immune 
system and cytokine signaling (Figure 1D). Interpretation of GSEA 
plots confirmed that type I IFN signaling was significantly enriched 
in ERCC1-deficient cells compared with isogenic WT cells (nor-
malized enrichment score [NES] = 2.11; FDR = 0.0057) (Figure 
1E). Consistent with this enrichment, refined analysis of the tran-
scriptomic data also identified several IFN-α/β/γ–inducible pro-
teins as being upregulated in ERCC1-defective cells, including 
several members of the STAT family (Supplemental Figure 1D). 
Cytokine signaling was also found to be significantly enriched in 
the A549-ERCC1–/– cell line (NES = 1.79; FDR = 0.0057) (Figure 
1F), and consistent with this result, we found an upregulation of 
several C-C motif and C-X-C motif chemokines in those cells (Sup-
plemental Figure 1E). In particular, the chemotactic chemokines 
CCL2, CCL5, CXCL1, CXCL2, CXCL5, CXCL8, and CXCL10 were 
upregulated greater than 5-fold in A549-ERCC1–/– cells (FDR < 
0.05). Considering the critical immunogenic and lymphoattractant 
properties of these chemokines (33), this suggested that ERCC1 
deficiency might contribute to the establishment of cancer cell–
autonomous immunity in NSCLC cells. These findings were also 
obtained in 2 independent A549-ERCC1–/– clones (c295 and c375), 
which showed similar significant enrichment in type I IFN signal-
ing on RNA-Seq profiling (NES = 2.54, FDR = 0.0062 for c295 and 
Figure 2. Loss of ERCC1 associates with increased 
STING expression in vitro and enhanced lym-
phocytic infiltration in human NSCLC samples. 
(A) Western blot illustrating ERCC1 and STING 
expression in A549-ERCC1WT/WT, A549-ERCC1+/–, 
A549-ERCC1–/– and A549-ERCC1–/– + isoform 202 
isogenic cell lines. (B) Scatter box plots of ERCC1 
protein expression (assessed by IHC staining) 
and the percentage of TILs (assessed through 
morphology) in a series of resected human NSCLC 
adenocarcinoma samples (n = 55). Tumors were 
classified according to the expression of ERCC1, 
and the corresponding level of TILs was plotted 
for each individual tumor. Mann-Whitney U test. 
(C) Representative images of ERCC1 and H&E 
stainings in 2 surgical specimens of resected lung 
adenocarcinoma. Case A shows low ERCC1 staining 
in tumor cells and high stromal TIL density; case B 
shows high ERCC1 staining in tumor cells and low 
stromal TIL density. Scale bars: 50 μm.
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reintroduced (herein referred to as “A549-ERCC1–/– + isoform 
202”). Strikingly, reexpression of ERCC1 in this isogenic model 
led to loss of STING protein expression (Figure 2A), suggesting 
ERCC1-dependent reversible modulation of STING expression. 
Of note, cGAS expression was also increased in A549-ERCC1–/– 
in the 2 other A549-ERCC1–deficient clones (Supplemental Fig-
ure 2G). In order to confirm that this observation was a primary 
effect of ERCC1 deficiency, we assessed STING expression in an 
isogenic cell line derived from the A549-ERCC1–/– clone in which 
the functional isoform of ERCC1 (isoform 202) had been stably 
Figure 3. PARPi generate CCFs in an ERCC1-dependent manner in 
NSCLC cells. (A) Assessment of olaparib (Ola) cytotoxicity in A549-ER-
CC1WT/WT versus A549-ERCC1+/–, A549-ERCC1–/–, and A549-ERCC1–/– + iso-
form 202 cell lines. Cells were treated with a range of doses of Ola and 
continuously exposed to the drug for 5 days. Shown are dose-response 
curves showing surviving fractions; mean ± SD, n = 4. (B) Representative 
immunofluorescence images of DMSO-, rucaparib- (Ruca-), and Ola- 
exposed A549-ERCC1WT/WT and A549-ERCC1–/– cells. Cells were exposed 
to 15 μM Ruca or 40 μM Ola during 72 hours. White arrows, CCFs; yellow 
arrows, micronuclei. Scale bar: 20 μm. (C) Automated quantification of 
CCFs in A549-ERCC1 isogenic cells exposed to increasing doses of Ruca 
or Ola (μM). Shown is CCF number per cell normalized to DMSO. Mean ± 
SD, n = 3; *P < 0.05, **P < 0.01, Kruskal-Wallis test and post hoc Dunn’s 
test, relative to DMSO control. Results shown are representative of 2 
experiments performed with similar results.
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cells (LFC = 0.5336, FDR = 0.0098). As activation of cGAS/
STING results in phosphorylation of TBK1, recruitment of IRF3, 
and eventually expression of type I IFN genes (16), this suggested 
that the observed transcriptomic profile could be linked to STING 
activation in A549-ERCC1–/– cells.
In order to evaluate whether this enhanced cell-autonomous 
immune signaling could shape the tumor microenvironment, we 
estimated the extent of tumor-infiltrating lymphocytes (TILs) in 
a series of 55 human tumor samples derived from patients with 
resected lung adenocarcinoma (stages I, II, and IIIA). ERCC1 sta-
tus in these tumors was evaluated by IHC as previously described 
(32), and TILs were assessed using a morphology-based coverage 
score. This analysis identified a statistically significant associa-
tion between low ERCC1 expression and high levels of TILs (P = 
0.0265, Mann-Whitney U test, Figure 2, B and C).
Taken together, these data suggest that ERCC1 loss results in 
a constitutive and cell-autonomous increase in STING expression 
and type I IFN signaling in NSCLC models in vitro. These observa-
tions are consistent with enhanced tumor lymphocytic infiltration 
in vivo in human NSCLC adenocarcinoma samples.
PARPi generate CCFs in an ERCC1 defect– and cell cycle–
dependent manner. As previously reported (28), A549-ERCC1–/– 
cells show enhanced sensitivity to PARPi when compared with 
A549-ERCC1WT/WT cells, an effect that we reconfirmed in short-
term survival assays (Figure 3A). We further hypothesized that 
PARPi — which not only inhibit the catalytic activity of PARP1, but 
also trap PARP1 onto the DNA, causing stalled replication forks 
and subsequent double-strand breaks (DSBs) (34) — might specifi-
cally favor the formation of CCFs and in turn trigger cGAS/STING 
signaling in ERCC1-defective tumor cells.
To test this hypothesis, we exposed A549-ERCC1 isogenic cell 
lines to increasing concentrations of 2 different clinical PARPi, 
rucaparib and olaparib, and monitored the presence of CCFs using 
immunofluorescence. For each PARPi, we selected concentrations 
surrounding the SF50 (dose generating 50% cell survival in short-
term assays, after 5 days of exposure to the drug) of the parental cell 
line; we therefore started with a dose corresponding to the SF80 of 
the WT cell line and applied a 2-fold increase at each subsequent 
dose to determine the final dose range. Although the number of 
CCFs in A549-ERCC1WT/WT, A549-ERCC1+/–, A549-ERCC1–/–, and 
A549-ERCC1–/– + isoform 202 cells was not significantly different 
in the absence of PARPi (Supplemental Figure 3A), we observed a 
dose-dependent increase in CCF number upon PARPi exposure, 
an effect that was significantly enhanced in A549-ERCC1–/– and 
A549-ERCC1+/– models compared with A549-ERCC1WT/WT cells 
(Figure 3, B and C; >6-fold difference at 10 μM olaparib, P = 
0.0016; >4-fold difference at 5 μM olaparib, P = 0.03; 2-way ANO-
VA, post hoc Šidák’s test), but not in A549-ERCC1–/– + isoform 202 
cells. These findings were further validated in the independent 
H1975-ERCC1 isogenic NSCLC model: in these cells, ERCC1 loss 
caused increased CCF levels in the absence of treatment (Supple-
mental Figure 3A; 2.5-fold increase, P = 0.0035, Welch’s t test), a 
phenotype that was enhanced upon PARPi exposure (Supplemen-
tal Figure 3, B and C).
BRCA1-defective tumor cells are also profoundly sensitive 
to PARPi (29). We therefore assessed whether the effects seen 
in ERCC1-defective cells could be reproduced in BRCA1-de-
fective cells. To do this, we used recently described isogen-
ic series derived from the BRCA1-mutant TNBC SUM149 cell 
line (35, 36). This isogenic series consists of 3 cell lines (Figure 
4A): one BRCA1-mutant parental line (SUM149-BRCA1mut); one 
BRCA1-mutant reverted line that is PARPi-resistant following 
restoration of the native BRCA1 reading frame and functional-
ity (35) (SUM149-BRCA1rev); and one SUM149 clone with PARPi 
resistance caused by loss of PARP1 (36) (SUM149-PARP1–/–). In 
the absence of PARPi, SUM149-BRCA1mut cells showed a signifi-
cantly higher number of CCFs compared with SUM149-BRCA1rev 
cells (>8-fold increase, P = 0.0233, Welch’s t test; Supplemental 
Figure 3A). Upon PARPi exposure, we observed a dose-depen-
dent increase in CCF number in SUM149-BRCA1mut cells, but 
not in SUM149-PARP1–/– cells, confirming the on-target effect of 
PARPi in triggering this phenotype (Figure 4, B and C); SUM149-
BRCA1rev cells showed an intermediate phenotype (Figure 4C), 
confirming that the generation of CCFs was a BRCA1-dependent 
process. As PARPi have been reported to modulate histone PARy-
lation and chromatin structure (37), thereby potentially promoting 
transcription of retroelements, we further confirmed the presence 
of chromatin (i.e., histone-bound DNA as opposed to naked DNA) 
by assessing the presence of histone H3 in cytoplasmic fractions. 
This demonstrated increased H3 levels after PARPi exposure in 
SUM149-BRCA1mut cells, but not in SUM149-PARP1–/– cells, thus 
confirming, respectively, the presence of cytoplasmic chromatin 
and the on-target effect of PARPi (Figure 4D). Consistent with 
this finding, assessment of H3K27me3 by immunofluorescence 
in the A549-ERCC1 isogenic cells revealed colocalization of this 
heterochromatin marker with CCFs in PARPi-exposed cells (Sup-
plemental Figure 3D).
As PARPi cause S phase–dependent DNA damage, we 
hypothesized that the observed CCFs might, at least in part, 
be micronuclei (19, 20). Micronuclei are signs of genomic or 
chromosomal instability which have two main characteristics: 
their formation is cell cycle dependent, as they arise during 
anaphase from lagging chromosomes or chromatid bridges fol-
lowing unresolved DNA lesions; and they contain heterochro-
Figure 4. PARPi generate CCFs in a DNA repair defect– and cell cycle- 
dependent manner. (A) Schematic of the generation of BRCA1-revertant 
and PARP1-knockout cell lines from the parental BRCA1-mutant SUM149 
TNBC cell line. (B) Representative immunofluorescence images of DMSO-, 
Ruca-, and Ola-exposed SUM149-BRCA1mut and SUM149-PARP1
–/– cells. 
Cells were exposed to 6 μM Ruca, 10 μM Ola, or DMSO (vehicle) during 72 
hours. White arrows, CCFs; yellow arrows, micronuclei. Scale bars: 20 μm. 
(C) Automated quantification of CCFs in SUM149-BRCA1mut, SUM149-
BRCA1rev, and SUM149-PARP1
–/– cells exposed to increasing doses of Ruca 
or Ola (μM). Shown is CCF number per cell normalized to DMSO. Mean ± 
SD, n = 3, Kruskal-Wallis test and post hoc Dunn’s test, relative to DMSO 
control. Results shown are representative of 2 experiments performed 
with similar results. (D) Western blot of histone H3 in the nuclear and 
cytoplasmic fractions of SUM149-BRCA1mut and SUM149-PARP1
–/– cells 
exposed to PARPi during 48 hours. β-Tubulin and lamin B1 were used as 
fraction purity controls. (E and F) Automated quantification of CCFs in 
A549-ERCC1WT/WT (E) and SUM149-BRCA1mut (F) cells exposed to increas-
ing doses of Ruca or Ola (μM) in the presence or absence of the cell cycle 
blocker CDK1i RO-3306. Shown is CCF number per cell normalized to 
DMSO. Mean ± SD, n = 3, Kruskal-Wallis test and post hoc Dunn’s test, 
relative to DMSO control. *P < 0.05, **P < 0.01, ***P < 0.001.
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cycle inhibitors: (i) the CDK1 inhibitor (CDK1i) RO-3306; (ii) 
hydroxyurea; and (iii) 5-fluorouracil. All 3 cell cycle inhibitors 
caused a complete abrogation of the PARPi-induced generation 
of CCFs, supporting that their formation was cell cycle depen-
dent (Figure 4E and Supplemental Figure 3, E and F). Similar 
observations were made in the SUM149-BRCA1mut cell line 
(Figure 4F). Immunofluorescence analysis of the costaining of 
H3K27me3 and lamin B1 in the A549-ERCC1 isogenic model 
revealed some structures typical of micronuclei (Supplemen-
tal Figure 3D), although the fragile lamin B1 envelope was not 
detectable around all PicoGreen/H3K27me3-colocalizing foci. 
Automated quantification of micronuclei revealed baseline pat-
terns similar to that of CCFs (Supplemental Figure 3A), as well 
as a consistent dose-dependent formation of micronuclei upon 
PARPi exposure, in both ERCC1- and BRCA1-isogenic models 
(Supplemental Figure 3, G and H). Consistent with our previous 
observations (Figure 3C and Figure 4C), this effect was more 
pronounced in A549-ERCC1–/– (Supplemental Figure 3G) and 
SUM149-BRCA1mut cells (Supplemental Figure 3H) and abrogat-
ed in the SUM149-PARP1–/– model.
These data support the hypothesis that PARPi exposure pro-
motes the accumulation of CCFs, some of which have charac-
teristics of micronuclei. This phenotype results from an on-tar-
get effect of PARPi, is cell cycle dependent, and is enhanced in 
ERCC1-defective NSCLC cells and other PARPi-sensitive models 
such as BRCA1-defective TNBC.
matin, initially surrounded by a fragile lamin B1 membrane that 
is eventually easily ruptured (19). We therefore first assessed 
the formation of CCFs in the presence of PARPi and upon cell 
cycle blockade in A549-ERCC1WT/WT cells, using 3 different cell 
Figure 5. PARPi-induced CCFs are detected by cGAS. (A) Representative 
immunofluorescence images of DMSO-, Ruca-, and Ola-exposed A549- 
ERCC1WT/WT and A549-ERCC1–/– cells. Cells were exposed to 15 μM Ruca or 
40 μM Ola during 72 hours. White arrows, CCFs; yellow arrows, micronuclei. 
Scale bars: 20 μm. Images corresponding to the DMSO condition originate 
from the same image field as those shown in Figure 3B. (B) Automated 
quantification of cytoplasmic cGAS foci in A549-ERCC1 isogenic cells exposed 
to increasing doses of Ruca or Ola (μM). Shown are numbers of cytoplasmic 
cGAS foci per cell normalized to DMSO. Mean ± SD, n = 3, Kruskal-Wallis 
test and post hoc Dunn’s test, relative to DMSO control. Results shown are 
representative of 2 experiments performed with similar results. (C) Repre-
sentative immunofluorescence images of DMSO-, Ruca-, and Ola-exposed 
SUM149-BRCA1mut and SUM149-PARP1
–/– cells. Cells were exposed to 6 μM 
Ruca, 10 μM Ola, or DMSO (vehicle) during 72 hours. White arrows, CCFs; yel-
low arrows, micronuclei. Scale bars: 20 μm. (D) Automated quantification of 
cytoplasmic cGAS foci in SUM149-BRCA1mut, SUM149-BRCA1rev, and SUM149-
PARP1–/– cells exposed to increasing doses of Ruca or Ola (μM). Shown are 
numbers of cytoplasmic cGAS foci per cell normalized to DMSO. Mean ± SD, 
n = 3; Kruskal-Wallis test and post hoc Dunn’s test, relative to DMSO control. 
Results shown are representative of 2 experiments performed, with similar 
results. (E) Scatter box plots displaying cGAS foci intensity for each colocal-
izing CCF foci in A549-ERCC1WT/WT and A549-ERCC1–/– cells exposed to DMSO 
(vehicle), 15 μM Ruca, or 40 μM Ola. n = 3, Kruskal-Wallis test and post hoc 
Dunn’s test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Figure 6. cGAS-mediated detection of PARPi-induced CCFs activates STING signaling in an ERCC1-dependent manner. (A and B) Western blot of pTBK1 in 
A549-ERCC1WT/WT and A549-ERCC1–/– cells (A) or H1975-ERCC1WT/WT and H1975-ERCC1–/– cells (B) upon PARPi exposure. Cells were exposed for 48 hours to DMSO 
(vehicle) and a range of doses of Ola (A), or DMSO, 25 μM Ruca, and 40 μM Ola (B). Lysates were probed with the indicated antibodies. (C) Western blot of pTBK1 in 
DMSO- or Ruca-treated H1975-ERCC1WT/WT cells in the context of siRNA silencing of cGAS/STING. Cells were transfected with RNAiMAX (Thermo Fisher Scientific), 
siCTRL, siSTING, sicGAS, or siSTING + sicGAS and exposed to DMSO (vehicle) or 25 μM Ruca, and lysates were probed with the indicated antibodies. (D) Western 
blot of pTBK1 in DMSO- or Ola-treated H1975-ERCC1WT/WT cells upon cell cycle blockade. Cells were exposed to DMSO or 20 μM or 80 μM Ola in the presence or 
absence of the cell cycle blocker CDK1i RO-3306. Lysates were probed with the indicated antibodies. Graph: pTBK1/TBK1 intensity was measured for each condition 
and normalized to DMSO. Mean ± SD, n = 3; *P < 0.05, Kruskal-Wallis test and post hoc Dunn’s test, relative to DMSO control.
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ERCC1WT/WT cells (Figure 6A and Supplemental Figure 4D). 
Consistent results were observed in the H1975-ERCC1 isogenic 
model, where an increase in pTBK1 was detected upon PARPi 
exposure, which was more pronounced in the H1975-ERCC1–/– 
cells (Figure 6B and Supplemental Figure 4E). This suggested 
the ERCC1 dependence of PARPi-induced TBK1 phosphoryla-
tion. Furthermore, while silencing of either cGAS or STING only 
moderately decreased PARPi-induced TBK1 phosphorylation in 
A549-ERCC1–/– cells (Supplemental Figure 4F), simultaneous 
silencing of both sensors allowed complete abrogation of pTBK1, 
as observed in H1975-ERCC1WT/WT cells (Figure 6C). We then 
evaluated pTBK1 in the SUM149-BRCA1 isogenic TNBC model. 
Consistent with results obtained in the NSCLC models, we found 
a dose-dependent increase in pTBK1 upon PARPi exposure in 
SUM149-BRCA1mut but not SUM149-BRCA1rev cells (Supplemen-
tal Figure 4G). A corresponding increase in phosphorylation of 
several transcription factors involved in the final steps of the 
STING signaling cascade, including p65–NF-κB, IRF3, and IRF7, 
confirmed activation of the pathway in SUM149-BRCA1mut cells 
(Supplemental Figure 4G).
Because CCFs can also be detected by alternative STING-in-
dependent pattern recognition receptors (PRRs), namely the Toll-
like receptor (TLR) and RIG-1-like receptor (RLR) pathways, we 
monitored the activation of those pathways after PARPi exposure. 
No activation of the TLR or RLR effectors could be detected upon 
PARPi exposure (Supplemental Figure 4, H and I), suggesting that 
the detection of CCFs following PARP inhibition is relatively spe-
cific to the cGAS/STING pathway.
Because our previous observations showed cell cycle depen-
dence of CCF formation (Figure 4, E and F), we monitored TBK1 
phosphorylation upon cell cycle blockade by CDK1i. Although 
CDK1i itself appeared to increase baseline pTBK1, we could 
detect an abrogation of the previously observed increase in TBK1 
phosphorylation upon PARPi exposure (Figure 6D). Collectively, 
these results support the notion that PARPi-induced CCFs activate 
cGAS/STING signaling and that this effect relies on the presence 
of specific DNA repair defects.
PARPi promote secretion of CCL5 and activate type I IFN signaling. 
Increased production of the chemotactic chemokine CCL5 has been 
previously reported in the context of DDR deficiency and following 
treatment with S phase–dependent DNA-damaging agents or ion-
izing radiation (17, 19, 20). We therefore hypothesized that PARPi 
might enhance CCL5 production, especially in ERCC1-deficient 
cells. Quantitative RT-PCR (RT-qPCR) analyses of CCL5 mRNAs 
revealed dose-dependent activation of CCL5 transcription in both 
A549-ERCC1–/– and A549-ERCC1WT/WT cells following PARPi expo-
sure (Figure 7A), while baseline expression levels were 12-fold higher 
in A549-ERCC1–/– cells compared with A549-ERCC1WT/WT cells (Fig-
ure 7B). Consistent with these observations, quantification of CCL5 
protein concentration in cell supernatants using ELISA revealed a 
similar dose-dependent increase in CCL5 secretion upon PARPi 
exposure in A549-ERCC1–/– but not A549-ERCC1WT/WT, A549-ER-
CC1+/–, or A549-ERCC1–/– + isoform 202 cells (Figure 7C). Depletion 
of STING and cGAS by siRNA resulted in a suppression of CCL5 
transcription and secretion, suggesting the involvement of cGAS/
STING in this process (Figure 7, A–C). Similarly, SUM149-BRCA1mut 
cells, but not SUM149-BRCA1rev cells, displayed enhanced expres-
PARPi-induced CCFs activate cGAS/STING signaling in 
ERCC1-deficient NSCLC cells. To investigate the potential of 
PARPi-induced CCFs to activate cGAS/STING signaling, we 
assessed the ability of cGAS to form foci through relocalization 
to CCFs. Immunofluorescence staining of cGAS in A549-ERCC1 
isogenic cell lines exposed to increasing concentrations of ruca-
parib or olaparib revealed a significant dose-dependent increase 
in the number of cytoplasmic cGAS foci in A549-ERCC1–/– and 
A549-ERCC1+/- cells, but not in A549-ERCC1WT/WT cells (Figure 5, 
A and B; P = 0.0122, P = 0.0123, and P = 0.1657, respectively; Kru-
skal-Wallis test). Similar results were obtained in the independent 
H1975-ERCC1 isogenic NSCLC model (Supplemental Figure 4, 
A and B). Increased formation of cytoplasmic cGAS foci was also 
detected in SUM149-BRCA1mut cells after PARPi exposure, at a 
higher level than in SUM149-BRCA1rev cells (1.4-fold difference at 
20 μM olaparib, P = 0.0033, 2-way ANOVA, post hoc Šidák’s test) 
(Figure 5, C and D). More importantly, no increase in cytoplasmic 
cGAS foci was detected in the PARPi-resistant SUM149-PARP1–/– 
cell line, supporting that the minimal levels of CCFs measured in 
this cell line did not trigger cGAS relocalization. Analysis of cGAS 
staining intensity within CCFs revealed a significant increase 
in cGAS foci/CCF colocalization upon PARPi exposure in both 
NSCLC ERCC1 isogenic models (Figure 5E and Supplemental 
Figure 4C; P < 0.0001, Kruskal-Wallis test), thus confirming that 
cGAS relocalized to CCFs following PARPi exposure.
We then investigated whether the detection of CCFs by 
cGAS could activate STING signaling. Analysis of phosphory-
lated TBK1 (pTBK1, a key downstream effector of STING signal-
ing) revealed a dose-dependent increase upon PARPi exposure 
in A549-ERCC1–/– and A549-ERCC1+/– models, but not A549- 
Figure 7. PARPi induce secretion of the chemotactic chemokine CCL5 in 
a cGAS/STING-dependent manner, and activate type I IFN signaling. (A) 
RT-qPCR analysis of RNA isolated from Ola-exposed A549-ERCC1WT/WT and 
A549-ERCC1–/– cells, in the presence or absence of cGAS/STING silencing by 
siRNA. Cells were transfected with siCTRL or sicGAS + siSTING and treated 
for 72 hours with DMSO or a range of doses of Ola (μM). CCL5 mRNAs were 
analyzed relative to GAPDH. Box-and-whisker plots show arbitrary units 
of gene expression, normalized to DMSO-treated control. Boxes indicate 
median and lower and upper quartiles; whiskers indicate the 5th to 95th per-
centile range; n = 12, Kruskal-Wallis test and post hoc Dunn’s test, relative 
to DMSO control. (B) RT-qPCR analysis of RNA isolated from A549-ERC-
C1WT/WT and A549-ERCC1–/– cells, in the presence or absence of cGAS/STING 
silencing by siRNA. Cells were transfected with siCTRL or sicGAS + siST-
ING. CCL5 mRNAs were analyzed relative to GAPDH. Shown are arbitrary 
units of gene expression, normalized to A549-ERCC1WT/WT DMSO-treated 
control. Mean ± SD, n = 4, 2-way ANOVA. (C) Quantitative analysis of CCL5 
secretion in A549-ERCC1 isogenic cell supernatants upon Ola exposure, 
in the presence or absence of cGAS/STING silencing by siRNA. Cells were 
transfected with siCTRL or sicGAS + siSTING and treated for 72 hours 
with DMSO or a dose range of Ola (μM). Supernatants were collected and 
analyzed by ELISA for detection of CCL5. Box-and-whisker plots show CCL5 
concentrations. Boxes indicate median and lower and upper quartiles; 
whiskers indicate the 5th to 95th percentile range; n = 4, Kruskal-Wallis 
test and post hoc Dunn’s test, relative to DMSO control. (D and E) GSEA 
of the REACTOME pathway “IFN-α/β signaling” in talazoparib- (Talazo-) 
versus DMSO-treated A549-ERCC1WT/WT cells (D) or A549-ERCC1–/– cells 
(E). A heatmap showing the genes of the pathway is shown below. n = 3; 
heatmap scale is a Z score. Purple, significantly DEGs with FDR < 0.05 and 
|LFC| > 1; green, significantly DEGs with FDR < 0.05 and |LFC| > 0.58; gray, 
nonsignificantly DEGs.*P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 8. ERCC1 deficiency and PARPi exposure potentiate IFN-γ–induced cell-surface PD-L1 expression. (A) Quantification of PD-L1 cell surface expres-
sion by flow cytometry in H1975-ERCC1WT/WT and A549-ERCC1WT/WT cells upon PARPi and IFN-γ exposure. Cells were treated for 48 hours with DMSO, 15 
μM Ruca, 3 μM Talazo, 10 μM niraparib (Nira), and/or 500 U/ml IFN-γ. MFI ± SD normalized to IFN-γ; n = 4, 2-way ANOVA and post hoc Tukey’s test. (B) 
Corresponding flow cytometry histograms; shown is the percentage of PD-L1–positive cells. (C) Quantification of PD-L1 cell surface expression by flow 
cytometry in A549-ERCC1WT/WT, A549-ERCC1–/–, H1975-ERCC1WT/WT, and H1975-ERCC1–/– cells treated for 48 hours with DMSO, 3 μM Talazo, and/or 500 U/ml 
IFN-γ. MFI ± SD, 2-way ANOVA and post hoc Tukey’s test. (D) RT-qPCR analysis of RNA isolated from A549-ERCC1WT/WT and A549-ERCC1–/– cells exposed 
to PARPi and/or IFN-γ. Cells were treated for 48 hours with DMSO, 3 μM Talazo, or 13.5 μM Ruca, and/or 500 U/ml IFN-γ. PD-L1 mRNAs were analyzed 
relative to GAPDH (to control for cDNA quantity). Shown are arbitrary units of gene expression, normalized to A549-ERCC1WT/WT DMSO-treated control. 
Mean ± SD, n = 3, 2-way ANOVA and post hoc Tukey’s test. (E) Quantification of PD-L1 cell surface expression by flow cytometry in SUM149-BRCA1mut and 
SUM149-PARP1–/– cells treated for 48 hours with DMSO, 3 μM Talazo, and/or 500 U/ml IFN-γ. MFI ± SD, n = 3, 2-way ANOVA and post hoc Tukey’s test. 
Corresponding flow cytometry histograms are shown at the bottom. *P < 0.05, **P < 0.01, ***P < 0.001.
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ically activate, in a cell-autonomous fashion in NSCLC cells, a type 
I IFN immune response that is enhanced in the context of ERCC1 
deficiency, and can be linked to the secretion of CCL5 in our models.
PARPi synergize with IFN-γ to induce cell-surface PD-L1 expres-
sion. PD-L1 is a major immune checkpoint protein expressed by 
tumor cells to evade immunosurveillance. PD-L1 induction is clas-
sically triggered by IFN-γ, which mediates the activation of type 
II IFN signaling cascade (38), but recent data suggest that plati-
num-based chemotherapies (39) as well as some PARPi (40) can 
also transiently enhance PD-L1 expression. Although the mech-
anisms underlying these effects are largely unknown, activation 
of PD-L1 expression following S phase–specific DNA damage has 
been associated with cGAS/STING recruitment (17). Because our 
previous data mostly pointed toward stimulation of type I IFN 
signaling through cGAS/STING in response to PARPi, we ques-
tioned whether PARPi could synergize with IFN-γ to induce PD-L1 
expression and whether ERCC1 status would influence this mod-
ulation. We exposed A549-ERCC1 isogenic and H1975-ERCC1 
isogenic cell lines to PARPi and/or IFN-γ, and monitored cell-sur-
face PD-L1 expression. Consistent with the published literature 
(40), we observed a significant dose-dependent upregulation of 
PD-L1 expression after treatment with rucaparib, talazoparib, or 
niraparib as monotherapy in both models (Figure 8, A and B, and 
sion and secretion of CCL5 following treatment with olaparib, which 
was reduced upon co-depletion of STING and cGAS (Supplemental 
Figure 5, A and B).
We next evaluated whether the production of other major 
chemokines was upregulated by PARPi exposure. Although 
a significant increase in IFNB1 transcription was observed in 
SUM149-BRCA1mut cells exposed to olaparib (Supplemental Fig-
ure 5C), no increase in the corresponding secreted protein could 
be detected in cell supernatants (Supplemental Figure 5D). Sim-
ilarly, no secretion of IFN-γ or TNF-α was detected after olaparib 
exposure in this cell line (Supplemental Figure 5E).
To comprehensively characterize cell-autonomous immuno-
modulation induced by PARPi, we performed RNA-Seq on A549-ER-
CC1WT/WT and A549-ERCC1–/– cells exposed to talazoparib, the most 
potent and specific clinical PARPi. This demonstrated significant 
upregulation of a number of genes involved in type I IFN signaling 
(Figure 7, D and E), which was associated with a significant enrich-
ment of the type I IFN signature in A549-ERCC1–/– cells (NES = 2.12; 
FDR = 0.0018). Although this upregulation was observed in both 
A549-ERCC1–/– and A549-ERCC1WT/WT cells, the corresponding 
enrichment was more modest in WT A549 cells (NES = 1.64; FDR 
= 0.0314), highlighting the role of ERCC1 deficiency in potentiating 
this phenotype. These data support the hypothesis that PARPi specif-
Figure 9. PARPi induce PD-L1 expression in 
patient-derived NSCLC cells and high PD-L1 
expression associates with low PARylation in 
human NSCLC samples. (A) Quantification of 
PD-L1 cell surface expression by flow cytometry 
in the EpCAM-positive cells of a pleural effusion 
sample upon PARPi and/or IFN-γ exposure. Cells 
were treated in vitro for 48 hours with DMSO or 10 
μM Nira, 500 U/ml IFN-γ, or both. MFI of a single 
staining is shown. (B) Scatter box plot showing 
PARylation levels and tumor cell expression of 
PD-L1 (as assessed by IHC staining) in a series of 
resected stage I/II NSCLC (invasive adenocarcino-
mas and squamous cell carcinomas) samples (n 
= 49). Mann-Whitney U test. (C) Representative 
images of PAR and PD-L1 IHC stainings in surgical 
specimens of NSCLC. Case A shows low PD-L1 
staining in tumor cells and high PARylation levels; 
case B shows high PD-L1 staining in tumor cells 
and low PARylation levels. Scale bars: 50 μm.
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el: although a significant synergy between talazoparib and IFN-γ 
could be observed in parental SUM149-BRCA1mut cells, this effect 
was completely abrogated in SUM149-PARP1–/– cells, where only 
IFN-γ could induce cell-surface PD-L1 (Figure 8E).
To explore this interaction between PARPi and type II IFN sig-
naling, we assessed whether PARPi could modulate the activation 
of STAT1, a key protein in the IFN-γ signaling pathway that mediates 
PD-L1 induction. Although exposure to PARPi monotherapy did 
not induce STAT1 phosphorylation, enhanced STAT1 phosphoryla-
tion was detected following combination treatment of PARPi plus 
IFN-γ, compared with IFN-γ alone (Supplemental Figure 6C). Inter-
estingly, this effect was abrogated upon cell cycle blockade with the 
CDK1i RO-3306, suggesting that progression through the cell cycle 
is required for the potentiation of STAT signaling by PARPi.
Supplemental Figure 6A). Interestingly, cotreatment with PARPi 
plus IFN-γ was synergistic and could potentiate the induction of 
PD-L1 expression (Figure 8, A and B). This induction was more 
profound in A549-ERCC1–/– and H1975-ERCC1–/– models when 
compared with their ERCC1-proficient counterparts, at both the 
cell surface and transcriptional levels (Figure 8, C and D). To assess 
the specificity of the observed effect, we evaluated the membrane 
expression of TLR4, an immune-related cell surface marker that 
has been described to be positively correlated with PD-L1 expres-
sion in NSCLC samples (41). No TLR4 induction could be detect-
ed under similar conditions, suggesting that PD-L1 induction 
may be relatively specific (Supplemental Figure 6B). We finally 
confirmed that the observed PD-L1 induction resulted from an 
on-target effect of PARPi using the SUM149-PARP1 isogenic mod-
Figure 10. Model of ERCC1 defect-dependent activation of cGAS/STING following PARPi exposure. (i) ERCC1WT/WT cells have a functional DDR and ade-
quately maintain genome integrity. (ii) Upon PARPi exposure, exogenous DNA damage is triggered, mostly initiated by PARP1 itself trapped onto the DNA 
at sites of spontaneous single-strand breaks (SSBs). (iii) During the S phase of the cell cycle, trapped PARP1 generates lesions that prevent the progres-
sion of replication forks, leading to fork stalling and subsequent formation of DSBs. In ERCC1WT/WT cells, most trapped PARP1 lesions are removed, which 
enables the processing of DSBs through HR and eventually allows replication to restart. Residual inadequately repaired lesions cause moderate formation 
of CCFs. (iv) The low levels of CCFs generated are unable to trigger the pTBK1/IRF3/NF-κB signaling cascade or subsequent transcription of type I IFN 
genes; PD-L1 is moderately induced. (v) ERCC1–/– cells are exposed to increased endogenous DNA damage following the loss of ERCC1. This generates min-
imal levels of CCFs. (vi) Upon PARPi exposure, ERCC1–/– cells are subjected to an additional exogenous source of DNA damage. (vii) During the S phase of 
the cell cycle, trapped PARP1 generates lesions that prevent the progression of replication forks, leading to stalling of forks and subsequent formation of 
DSBs. In the absence of ERCC1, trapped PARP1 lesions cannot be adequately resolved, which triggers increased DSBs and eventually generates high levels 
of CCFs. (viii) CCFs are detected by cGAS and, due to the enhanced expression of STING in ERCC1–/– cells, these efficiently activate cGAS/STING signaling. 
Activated STING homodimer phosphorylates TBK1, which in turn phosphorylates IRF3 and NF-κB; this triggers their translocation into the nucleus and 
results in the transcription of type I IFN genes: CCL5 and other type I IFN cytokines are secreted. Higher PD-L1 expression is induced at the cell surface.
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pTBK1/pIRF3/type I IFN response in cancer cells. Importantly, 
this response was exacerbated in ERCC1-deficient NSCLC con-
texts. We further showed that ERCC1 deficiency and PARPi were 
synergistic with IFN-γ in inducing PD-L1 expression (Figures 8 
and 9), thereby providing a rationale for strategies combining 
PARPi and anti–PD-(L)1 therapies in appropriately molecularly 
selected populations.
Despite significant improvements in outcome brought by 
the advent of anti–PD-(L)1 therapies, NSCLC still represents the 
leading cause of cancer-related death. Only a minority of patients 
currently benefit from ICI, and strategies to turn “cold” tumors 
into “hot” tumors are being actively investigated. Interestingly, 
high TIL levels correlate with improved survival following neoad-
juvant therapy in TNBC (42) — an observation that was also made 
in some NSCLC series in the adjuvant setting (43). In line with 
our findings, preclinical data evaluating rucaparib in combination 
with anti–PD-(L)1 in syngeneic models of ovarian cancer have sug-
gested a possible role for PARPi in promoting tumor lymphocytic 
infiltration, and increased benefit compared with anti–PD-(L)1 
monotherapies in BRCA1-mutated tumors (44). Our observation 
that PARPi trigger cGAS/STING signaling (Figures 5 and 6) and 
favor secretion of lymphoattractant chemokines such as CCL5 in 
ERCC1-deficient NSCLC (Figure 7) suggests that PARPi could be 
used as immunomodulatory agents to trigger lymphocytic infil-
tration in this histotype. Conversely, adding anti–PD-(L)1 thera-
pies to PARPi might overcome the immune escape mechanisms 
resulting from PARPi-induced PD-L1 upregulation on tumor cells. 
Importantly, recent data from the large randomized double-bind 
phase III study Keynote 189 (NCT02578680) evaluating the 
combination of pembrolizumab and platinum–based chemother-
apy in first-line metastatic NSCLC have reported impressive ben-
efits in progression-free and overall survival (HR for death = 0.49; 
95% CI, 0.38–0.64; P < 0.001) (1). These results changed prac-
tice, setting up the framework for recommending anti–PD-(L)1 
therapy in combination with platinum-based doublet chemo-
therapy in first-line advanced NSCLC. Interestingly and contrary 
to previous studies evaluating anti–PD-(L)1 monotherapy, this 
benefit was observed across all subgroups and was independent 
of baseline PD-L1 tumor expression score, suggesting that other 
tumor characteristics — such as DDR status — might play a role 
in response to this combination. Platinum sensitivity is a relevant 
phenotypical biomarker of sensitivity to PARPi (27), which sug-
gests that PARPi — which are much better tolerated and do not 
cause severe bone marrow toxicity — might represent an inter-
esting alternative or complement (in the maintenance setting) to 
platinum-based chemotherapy in combination with anti–PD-(L)1 
agents in NSCLC. The development of clinical trials addressing 
this question is underway.
TMB is an important determinant of response to ICI (9, 
10). While various DDR defects have been shown to critical-
ly contribute to the accumulation of mutations in the tumor 
genome, only some of them have proven their predictive val-
ue as biomarkers of response to anti–PD-(L)1 therapy (6, 45). 
ERCC1 deficiency has been associated with increased mutation 
frequency and genomic instability in mice (46), an observation 
that is consistent with the known roles of ERCC1 in processes 
that ensure chromosomal stability and maintenance of genome 
We next sought to assess whether these mechanisms would 
also operate in patients and exposed fresh cells from a patient’s 
NSCLC pleural effusion sample to PARPi and IFN-γ. After selec-
tion of epithelial cell adhesion molecule–positive (EpCAM+) 
cells, we quantified PD-L1 cell-surface expression by flow cytom-
etry. This revealed a similar PD-L1 induction upon PARPi expo-
sure, which was again potentiated by IFN-γ, consistent with our 
in vitro findings (Figure 9A).
As PARPi have a dual mechanism of action (i.e., inhibition of 
the PARylation catalytic activity of PARP1 and PARP1 trapping), we 
also sought to evaluate whether PARylation levels or PARP1 expres-
sion would correlate with PD-L1 expression in human tumor sam-
ples. We performed immunostaining of PAR, PARP1, and PD-L1 in 
a series of 49 resected stage I/II NSCLC samples. No correlation 
between PARP1 expression and PD-L1 staining (Supplemental 
Figure 6, E and F) was found. A significant inverse correlation was 
found between PAR and PD-L1 levels on tumor cells (mean PARyla-
tion H-score of 100 in PD-L1–low vs. 60 in PD-L1–high tumor cells; 
P = 0.003; Mann-Whitney U test; Figure 9, B and C) but not PD-L1 
expression on immune cells (Supplemental Figure 6D), consistent 
with a previous report in breast cancer specimens (40).
A proposed model to explain cGAS/STING activation following 
PARPi exposure in tumor cells with ERCC1 deficiency. Although 
several scenarios may explain our findings, we propose the fol-
lowing model, which is consistent with our observations (Figure 
10): ERCC1WT/WT cells adequately repair endogenous DNA lesions. 
PARPi exposure causes DNA damage, mostly initiated by PARP1 
itself trapped onto the DNA at sites of spontaneous single-strand 
breaks. Trapped PARP1 generates stalled replication forks and 
subsequent DSBs during DNA replication. In ERCC1WT/WT cells, 
trapped PARP1 lesions can be adequately excised, a process in 
which ERCC1 is thought to play a major role (28). Following exci-
sion, repair of DSBs occurs through HR, and replication restarts. 
Residual unrepaired lesions cause minimal formation of CCFs, 
which are insufficient to trigger cGAS/STING signaling (Figure 
10, i–iv). By contrast, ERCC1–/– cells are exposed to increased 
levels of endogenous DNA damage, which are further enhanced 
upon PARPi exposure. Trapped-PARP1 lesions cannot be appro-
priately resolved in the absence of ERCC1 (28), which prevents 
the subsequent processing of DSBs through HR (Figure 10, v–vii). 
This results in the accumulation of stalled replication forks, subse-
quent DSBs, and unrepaired DNA lesions, which eventually caus-
es increased micronuclei formation and CCF generation (Figure 
10, vii). These are detected by cGAS, which activates the STING/
pTBK1 cascade and results in the transcription of type I IFN genes, 
including CCL5 (Figure 10, viii).
Discussion
DNA repair deficiency is a hallmark of cancer that has been ther-
apeutically exploited for more than 50 years using DNA-damag-
ing cytotoxic chemotherapies and more recently, with the advent 
of targeted DNA repair inhibitors such as PARPi, using synthetic 
lethality. Here, we show that multiple clinical PARPi can trigger 
the activation of innate immune pathways in a cell-autonomous 
fashion in vitro. By studying multiple isogenic models of DDR 
deficiency or PARPi resistance, and using fresh and archived 
tumor samples, we found that PARPi can elicit a cGAS/STING/
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BRCA1/2-mutant breast or ovarian cancers, other histologies, 
such as NSCLC in which anti–PD-(L)1 therapies have already 
shown impressive results, might also benefit from such associ-
ation. Basket clinical trials are planned to be launched soon to 
explore this question.
Methods
Additional methods are described in Supplemental Methods.
Study design. The aim of this study was to assess the immu-
nomodulatory potential of PARPi, their ability to trigger specific 
cancer cell–associated immune responses, and their potential to 
enhance cancer cell immunogenicity through cell-autonomous 
mechanisms. Our prespecified hypothesis was that PARPi might 
have intrinsic immunomodulatory properties capable of activating 
immune signaling in a cell-autonomous fashion in cancer cells, spe-
cifically in those harboring DDR defects. Hence, we used a combi-
nation of in vitro isogenic systems of DDR-deficient and PARPi-sen-
sitive or -resistant NSCLC and TNBC. All laboratory experiments 
were performed in at least 3 independent biological replicates to 
allow appropriate statistical calculations, using multiple well-char-
acterized models and several PARPi evaluated in dose response 
experiments at clinically relevant concentrations. RNA-Seq was 
performed to generate at least 20 million reads per sample. For each 
condition, 3 biological replicates were included in the RNA-Seq 
analysis. Clinically relevant findings were further assessed in retro-
spectively analyzed archived patient tumor samples as well as one 
fresh prospectively collected pleural effusion.
Cell lines. SUM149, A549, and H1975 cells were obtained 
from ATCC. The generation of SUM149-BRCA1rev and SUM149-
PARP1–/– secondary mutant cell lines was performed using CRISPR/
Cas9 site-directed mutagenesis, as previously described (35, 36). 
The secondary mutant cell lines A549-ERCC1–/– and H1975-ER-
CC1–/– were generated using zinc finger nuclease gene targeting, 
as described previously (31). SUM149 cells were cultured in Ham’s 
F12 nutrient mixture with 10% FBS, 1 μg/ml insulin, and 500 ng/
ml hydrocortisone. A549 and H1975 cells were cultured, respec-
tively, with high-glucose DMEM and RPMI 1640 medium with 10% 
FBS. The cells were cultured under physiological conditions at 37°C 
and 5% CO2. All cell lines were short tandem repeat (STR) typed 
using StemElite ID (Promega) to confirm identity prior to the study, 
and verified for mycoplasma contamination every 2 months using 
MycoAlert (Lonza).
Drugs and chemicals. The PARPi olaparib (AZD-2281, Astra Zen-
eca), rucaparib (PF-01367338, Clovis Oncology), and talazoparib 
(BMN-673, Pfizer) were purchased from Selleck Chemicals. Nirapa-
rib (MK-4827, Tesaro) was obtained from MedChemExpress. Inhibi-
tor stock solutions were prepared in DMSO and stored in aliquots at 
–80°C. Hydroxyurea (HU), 5-fluorouracil (5-FU), and the CDK1 inhib-
itor RO-3306 were obtained from Sigma-Aldrich. IFN-γ-1b (IMUKIN) 
was purchased from Boehringer.
Immunofluorescence and image analysis. Immunofluorescence 
assays were performed in 96-well plates. Cells were fixed in 4% para-
formaldehyde (PFA) in PBS during 20 minutes at room temperature 
(RT), washed twice with PBS, and permeabilized with 0.5% Triton 
X-100 in PBS for 10 minutes. After 2 additional washes, cells were 
blocked with 2% BSA, 2% FBS in PBS (IFF) for 1 hour at RT. Cells 
were then incubated with primary antibodies in IFF at 4°C overnight. 
integrity, such as the interstrand crosslink DNA repair path-
way (47) and resolution of Holliday junctions (48). However, 
no formal studies have yet been conducted to assess whether 
ERCC1 status might influence TMB in NSCLC. This would be 
best addressed by interrogating large datasets (e.g., The Can-
cer Genome Atlas [TCGA]) for an inverse correlation between 
ERCC1 isoform 202 expression and TMB. Furthermore, wheth-
er ERCC1 status itself represents an independent predictive 
biomarker of response to anti–PD-(L)1 in NSCLC is currently 
unknown and deserves further investigation.
Although our study focused on ERCC1 — the most frequent 
DDR deficiency in NSCLC — we can hypothesize that our find-
ings may be applicable to other DDR defects detected at a low-
er frequency in NSCLC. For example, BRCA1, BRCA2, ATM,and 
MSH2 (mutated in 5%, 6%, 9%, and 3% of NSCLC cases, respec-
tively; ref. 49) have also been associated with PARPi sensitivity 
and type I IFN signature (50–53). Interestingly, Teo et al. recently 
reported that somatic DDR alterations that were associated with 
improved clinical outcomes in platinum-treated patients with 
advanced urothelial carcinoma (54) also correlated with longer 
progression-free survival and overall survival upon anti–PD-(L)1 
therapy (15). The authors reported that 25% of patients present-
ed tumors with alterations in DDR genes, the most commonly 
altered genes being ATM, POLE, BRCA2, ERCC2, FANCA, and 
MSH6. Overall, these observations suggest that the interplay 
among DDR deficiency, platinum or PARPi sensitivity, and anti-
cancer immune response operates in several tumor types and can 
involve multiple DDR defects.
cGAS is a potent sensor of almost any form of cytoplasmic 
DNA. It can detect free DNA, arising from reverse transcription 
of endogenous retroviruses (55) or mitochondrial DNA instabil-
ity (56); and micronuclei, which arise from genomic instability 
and display chromatin-like structures, sometimes surround-
ed by a fragile lamin B1 membrane (19). Our data provide evi-
dence that clinical PARPi can induce cytosolic DNA (Figures 3 
and 4), which is at least in part in the form of micronuclei, and 
subsequently activates cGAS/STING signaling (Figures 5 and 
6). In particular, our observation that these effects are abrogat-
ed in PARP1-null cells supports a direct on-target effect of these 
drugs, which is mostly mediated by their PARP-trapping poten-
tial (36). Furthermore, use of several specific isogenic models 
demonstrated that this effect is enhanced in several DNA repair–
deficient contexts, notably ERCC1 and BRCA1 deficiency. This 
extends and is consistent with previous publications that report-
ed activation of cGAS/STING by micronuclei following either 
ionizing radiation (19, 20) or S phase–specific chemotherapies 
(17, 18), and published data that showed PARPi-mediated induc-
tion of IFN signals (notably increased STAT1 phosphorylation) 
in BRCA1-deficient contexts (20). Importantly, our observation 
that the immune phenotype of the ERCC1-heterozygous mod-
el closely resembles that of the ERCC1–/– clones suggests that 
our findings may be clinically relevant for NSCLC, where some 
residual expression of ERCC1 is usually retained.
In conclusion, we provide a scientific rationale for assessing 
PARPi in combination with anti–PD-(L)1 therapy in molecularly 
selected DNA repair–deficient populations. While several clin-
ical trials are currently combining PARPi with anti–PD-(L)1 in 
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 2 2 7jci.org   Volume 129   Number 3   March 2019
Statistics. No statistical methods were used to predetermine sam-
ple size. The experiments were not randomized. The investigators were 
not blinded to allocation during experiments and outcome assessment. 
All bar graphs show mean values with error bars (SD); 95% confidence 
intervals were used, and significance was considered when P was less 
than 0.05; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Study approval. No specific approval was required for this study, as 
no experiments were conducted in animals or humans. Informed con-
sent was obtained from patients for the collection and study of pleural 
effusion samples.
Data availability. All RNA-Seq data sets generated as part of 
this study are publicly available at the European Nucleotide Archive 
(https://www.ebi.ac.uk/ena), under accession number PRJEB30090.
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The cells were then washed 3 times with PBS, each for 10 minutes, 
followed by incubation with Alexa Fluor 594–conjugated rabbit and 
Alexa Fluor 647–conjugated mouse secondary antibodies (Thermo 
Fisher Scientific), 1 μg/ml DAPI, and 1:400 PicoGreen (Thermo Fish-
er Scientific) in IFF for 1 hour at RT. After that, cells were washed 
again 3 times with PBS, and 100 μl PBS was finally added to each well 
prior to imaging. Plates were imaged using an Operetta high-con-
tent imaging system (PerkinElmer). Quantification of the number 
of CCFs, micronuclei, and cGAS foci was performed under identical 
microscopy settings between samples, using the Columbus image 
analysis system (PerkinElmer). Twenty-five randomly selected fields 
containing more than 200 cells were analyzed within 3 individual 
replicates for each sample.
Detection of secreted cytokines. Detection of secreted cytokines in 
cell supernatants was performed through ELISA detection. Culture 
media were collected after a 72-hour culture, and cell numbers were 
counted for normalization. The media were dispensed in 96-well 
V-bottomed plates and centrifuged at 500 g for 5 minutes to pellet cells 
and debris. The resulting supernatants were used for ELISA detection 
with the following kits: Human CCL5 ELISA MAX Deluxe kit (catalog 
440806), Human IFN-γ ELISA MAX Standard kit (catalog 430103), 
and Human TNF-α ELISA MAX Deluxe kit (catalog 430206) from 
BioLegend; and Human IFN-β ELISA kit (catalog 41410-1) from PBL 
Assay Science. Assays were performed in 4 replicates following the 
manufacturers’ protocols. Absorbance was evaluated using a VICTOR 
multilabel plate reader (PerkinElmer).
Flow cytometry analyses. Cells were detached using Versene solu-
tion (Thermo Fisher Scientific) and transferred to round-bottom FACS 
tubes. After 5 minutes of centrifugation at 500 g, the cells were washed 
with PBS and incubated at 4°C for 30 minutes with primary antibod-
ies, diluted in 5% BSA in PBS. The supernatants were removed after 
centrifugation, and the cells were washed again twice with PBS. The 
pellets were finally diluted in 250 μl PBS containing 1 μg/ml propidi-
um iodide (PI) prior to analysis. Cell-surface expression of PD-L1 and 
TLR-4 was quantified and analyzed by flow cytometry on an LSR II 
flow cytometer (BD Biosciences). PI was used as a viability marker. 
Data analysis was performed using the FlowJo software package.
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